TCB2 Antibody

Abstract

TCB2 is a novel anti-human interleukin-2 (IL-2) monoclonal antibody that has shown promising results in cancer immunotherapy. This antibody selectively stimulates CD8 T and natural killer (NK) cells while minimally activating regulatory T cells (Tregs), resulting in enhanced anti-tumor immune responses. This document provides a collection of frequently asked questions about TCB2 antibody for researchers, covering its mechanism of action, structural properties, experimental methodologies, and clinical applications. The information is drawn from recent scientific literature and structured to address both fundamental concepts and advanced research considerations.

What is TCB2 antibody and how does it differ from other anti-IL-2 antibodies?

TCB2 is a monoclonal antibody targeting human interleukin-2 (hIL-2) that was specifically developed to selectively stimulate CD8 T and NK cells without overtly activating Tregs. It belongs to a series of anti-human IL-2 antibodies (TCB1-3) that were designed to preferentially work on the dimeric IL-2 receptor by blocking the CD25 binding motif .

Unlike previously developed anti-IL-2 antibodies such as NARA1, TCB2 has unique complementarity-determining regions (CDRs) with only about 34% sequence homology to NARA1 . This unique structure allows TCB2 to bind to the central area of the hIL-2Rα binding region on hIL-2, whereas NARA1 recognizes the top part of hIL-2 . This binding profile gives TCB2 its distinctive immunostimulatory properties.

What is the mechanism of action of TCB2 antibody?

TCB2 antibody works by binding to human IL-2 and forming an IL-2/TCB2 complex (hIL-2/TCB2c) that selectively blocks the interaction between IL-2 and IL-2Rα (CD25), which is predominantly expressed on Tregs . This selective blockade enhances the anti-tumor effects of IL-2 by:

• Redirecting IL-2 signaling through the intermediate-affinity IL-2 receptor (consisting of IL-2Rβ and IL-2Rγ) expressed on CD8 T cells and NK cells

• Inducing robust expansion of memory phenotype CD8 T cells (60-fold) and NK cells (18-fold)

• Limiting Treg proliferation (only 5-fold expansion)

• Resulting in an average eightfold increase in the ratio of memory phenotype CD8 T cells to Tregs

Additionally, structural analysis reveals that TCB2 binding to hIL-2 induces an allosteric effect that increases the affinity for the heterodimeric IL-2 receptor, IL-2R(β + γ), on effector T cells .

How is TCB2 prepared for experimental use?

For experimental applications, the TCB2/IL-2 complex is prepared as follows:

• Human IL-2 (hIL-2) at 500-1000 μg/ml and TCB2 antibody at 500 μg/ml are mixed at a 1:10 molecular ratio (or as otherwise indicated for specific experiments)

• The mixture is incubated for 30 minutes at room temperature

• The complex is then diluted in PBS to achieve the desired injection volume (typically 200 μl per injection for mouse models)

This preparation method ensures the formation of stable complexes between hIL-2 and TCB2 that maintain their biological activity.

What are the main applications of TCB2 in cancer research?

TCB2 has several important applications in cancer research:

• Tumor growth inhibition studies: hIL-2/TCB2c has been shown to strongly inhibit the growth of multiple tumor types including B16F10 melanoma, MC38 colon adenocarcinoma, and CT26 colorectal carcinoma .

• Combination therapy investigations: TCB2 shows remarkable synergy with immune checkpoint inhibitors such as anti-CTLA-4 or anti-PD1 antibodies, resulting in almost complete regression of implanted tumors and resistance to secondary tumor challenge .

• Immune cell expansion studies: TCB2 can be used to study selective expansion of CD8 T and NK cells without significant Treg activation, allowing for investigation of effector-to-regulatory T cell balance in tumor microenvironments .

• Mechanistic studies of IL-2 signaling: The unique binding properties of TCB2 make it valuable for studying how modulation of IL-2 receptor interactions affects downstream signaling and immune cell function .

What structural features of TCB2 determine its selective binding to IL-2?

The crystal structure of TCB2-Fab in complex with human IL-2 at 2.5 Å resolution reveals several key structural features that determine its selective binding:

• The epitope of hIL-2 recognized by TCB2 is mainly composed of residues from:

  • AB loop (P34, K35, T37, R38, L40, T41, F42, K43, Y45)

  • Helix B (E62, P65, E68, K76)

  • CD loop (T111)

• Arginine 38 (R38) of hIL-2 plays a central role in recognition by TCB2, with approximately 144 Ų of accessible surface area from R38 buried after binding of TCB2. This interaction involves F105 from CDR3 of the heavy chain and D32, E50, Y96 from the light chain of TCB2 .

• The buried surface area between TCB2 and hIL-2 is about 1,900 Ų, which is within the average value for antibody-antigen complexes .

• TCB2 binds to the central area of the hIL-2Rα binding region on hIL-2, while NARA1 (another IL-2Rα mimicking antibody) recognizes the top part of hIL-2, resulting in different functional outcomes despite similar blocking effects .

These structural features collectively enable TCB2 to selectively block IL-2's interaction with IL-2Rα while maintaining or enhancing its binding to the IL-2Rβ/γ complex.

How does the binding affinity of TCB2 compare to other anti-IL-2 antibodies?

The binding characteristics of TCB2 have been compared to other anti-IL-2 antibodies using surface plasmon resonance:

This higher affinity and slower dissociation rate likely contribute to TCB2's superior in vivo efficacy compared to other anti-IL-2 antibodies.

What are the optimal dosing parameters for TCB2 in mouse tumor models?

Based on the research data, the following dosing parameters have been established for effective TCB2 use in mouse tumor models:

• Effective dose range:

  • In dose-response studies, hIL-2/TCB2c administered at a dose as low as 0.8/8 μg (IL-2/TCB2) was effective in significantly increasing the MP CD8/Treg ratio (7.7-fold increase compared to 3.7-fold with hIL-2/MAB602c at the same dose)

• Administration schedule:

  • For tumor growth inhibition studies, the complex is typically administered repeatedly over several days

  • For T cell proliferation assays, daily injections for four consecutive days followed by analysis 48 hours after the last injection have been effective

• Combination therapy dosing:

  • When combined with anti-PD1 antibody (200 μg/injection), hIL-2/TCB2c treatment resulted in complete regression of tumors in 100% of mice (7 out of 7)

  • The humanized version (hIL-2/hTCB2c) with the same anti-PD1 regimen achieved 90% complete regression (8 out of 9 mice)

• Route of administration:

  • Most studies use intraperitoneal injection for delivery of the hIL-2/TCB2c complex

How does the humanized form of TCB2 compare with the murine version in terms of efficacy?

For clinical applications, a humanized form of TCB2 (hTCB2) has been developed and compared to the murine version:

• Binding affinity:

  • The selected humanized TCB2 clone has approximately 70% of the affinity of the murine version

• Immune cell expansion:

  • Comparative studies in B6 mice showed that hIL-2/hTCB2c induces comparable expansion of CD8 T, NK, and Treg cells to that of hIL-2/TCB2c

• Anti-tumor efficacy:

  • In the MC38 tumor model with anti-PD1 combination therapy, hIL-2/hTCB2c achieved 90% complete tumor regression (8 out of 9 mice) compared to 100% (7 out of 7) with hIL-2/TCB2c

  • When used alone, hIL-2/hTCB2c resulted in 40% tumor rejection

• Safety profile:

  • The humanized form maintains the selective immune cell targeting of the murine version, suggesting a similar safety profile

This comparative data indicates that the humanized TCB2 retains essentially equivalent functional properties to the murine version, making it suitable for potential clinical development.

What cellular and molecular assays can be used to evaluate TCB2 efficacy?

Several assays have been developed to evaluate the efficacy of TCB2:

• Cell proliferation assays:

  • CellTrace Violet (CTV) labeling of lymphocytes followed by adoptive transfer to monitor in vivo proliferation of specific T cell subsets

  • MTT-based CTLL2 cell proliferation assay to assess IL-2 bioactivity in the presence of TCB2

• Flow cytometry analyses:

  • Quantification of expansion of memory phenotype CD8 T cells, NK cells, and Tregs

  • Assessment of functional markers like granzyme B expression and IFNγ production in CD8 T cells

• Binding assays:

  • Enzyme-linked immunosorbent assay (ELISA) to assess antibody cross-reactivity and binding site competition

  • Surface plasmon resonance for affinity measurement using platforms like Biacore T100/T200

• Molecular characterization:

  • CDR region sequencing of antibody heavy and light chains using RNA isolation, cDNA synthesis, and PCR amplification

  • X-ray crystallography to determine the precise structure of the hIL-2/TCB2 complex

• In vivo tumor models:

  • Subcutaneous tumor growth measurement using various cancer cell lines (B16F10, MC38, CT26)

  • Combination therapy models with checkpoint inhibitors to assess synergistic effects

How does TCB2 synergize with immune checkpoint inhibitors?

The synergy between TCB2 and immune checkpoint inhibitors represents one of its most promising applications in cancer immunotherapy:

• Mechanism of synergy:

  • TCB2 expands the pool of effector T cells and NK cells, providing more immune cells that can target tumors

  • Checkpoint inhibitors (anti-PD1, anti-CTLA-4) remove the inhibitory signals that would otherwise dampen these expanded effector cells

  • This creates a "two-pronged" approach: increasing the number of effector cells while simultaneously removing their inhibitory brakes

• Experimental evidence:

  • In the MC38 tumor model, anti-PD1 alone achieved 25% tumor rejection

  • hIL-2/hTCB2 complex alone achieved 40% tumor rejection

  • The combination resulted in 90-100% complete tumor regression

• Long-term immunity:

  • The combination treatment not only led to tumor regression but also conferred resistance to secondary tumor challenge, indicating the development of immunological memory

• Rationale for clinical translation:

  • Checkpoint inhibitors currently have response rates of about 20-30% in clinical settings

  • Combination with IL-2-based therapies like TCB2 could potentially increase these response rates by addressing non-responsive or poorly infiltrated tumors

  • TCB2 could help render "cold" tumors (poorly infiltrated) into "hot" tumors (well-infiltrated with immune cells) that are more susceptible to checkpoint inhibitor therapy

What are the recommended protocols for preparing and storing TCB2 for research use?

Based on the available research data, the following protocols are recommended for TCB2 preparation and storage:

• Antibody production:

  • TCB2 can be expressed using hybridoma cell culture (for murine version)

  • For the humanized version (hTCB2), the ExpiCHO Expression System has been used successfully

  • Purification should be performed with protein G resin to achieve >95% purity

• Complex formation with IL-2:

  • Mix purified hIL-2 (500-1000 μg/ml) with TCB2 (500 μg/ml) at a 1:10 molecular ratio

  • Incubate for 30 minutes at room temperature

  • Dilute in PBS to the desired concentration for experimental use

• Storage considerations:

  • The hIL-2/TCB2 complex has been shown to remain stable for more than a week at room temperature

  • For longer-term storage, it is recommended to store the antibody and cytokine separately at -20°C or -80°C

  • Avoid repeated freeze-thaw cycles by preparing small aliquots

• Quality control:

  • Size exclusion chromatography can be used to confirm proper complex formation

  • Functional testing using CTLL2 cell proliferation assays can verify bioactivity

What techniques are available for analyzing the structural properties of the TCB2-IL-2 complex?

Several advanced techniques have been employed to analyze the structural properties of the TCB2-IL-2 complex:

• X-ray crystallography:

  • The crystal structure of TCB2-Fab in complex with hIL-2 has been determined at 2.5 Å resolution

  • This technique revealed the precise binding epitope and the conformational changes induced by TCB2 binding

• Size exclusion analysis:

  • Used to confirm that hIL-2 and Fab of TCB2 form a stable 1:1 complex in solution

  • Can also be used to monitor complex stability over time

• Surface plasmon resonance (SPR):

  • Platforms like Biacore T100/T200 have been used to measure binding kinetics

  • Provides quantitative data on association and dissociation rates

  • Has determined the dissociation constant (KD) of TCB2 for hIL-2 to be 8.11 × 10⁻¹¹ M

• Molecular dynamics (MD) simulations:

  • While not explicitly mentioned for TCB2, MD simulations are commonly used with antibody-antigen complexes to study dynamic interactions and could be applied to the TCB2-IL-2 complex

• CDR region sequencing:

  • RNA isolation from hybridoma cells followed by cDNA synthesis and PCR amplification

  • Allows determination of the unique binding regions of TCB2 that distinguish it from other anti-IL-2 antibodies

How can researchers assess the functional selectivity of TCB2 for different immune cell populations?

Assessing the functional selectivity of TCB2 for different immune cell populations is critical for understanding its immunotherapeutic potential. Several methods have been established:

• In vivo expansion assays:

  • Administer hIL-2/TCB2c to mice followed by flow cytometric analysis of various lymphocyte populations

  • Compare the fold expansion of memory phenotype CD8 T cells, NK cells, and Tregs

  • Quantify the ratio of effector (CD8 T, NK) to regulatory (Treg) cells as a measure of selectivity

• Adoptive transfer experiments:

  • Label lymphocytes from Thy1.1+ Foxp3-eGFP+ mice with CellTrace Violet (CTV)

  • Transfer labeled cells into recipient mice

  • Administer hIL-2/TCB2c and analyze proliferation of specific donor cell populations

• Functional marker analysis:

  • Measure the expression of functional markers such as granzyme B in CD8 T cells

  • Assess cytokine production (e.g., IFNγ) by intracellular staining

  • Evaluate the cytotoxic potential of expanded NK cells

• Comparative analysis:

  • Side-by-side comparison with other IL-2 complexes (e.g., hIL-2/MAB602c)

  • Dose-response studies to determine relative potency in expanding different cell populations

• Receptor occupancy studies:

  • Analysis of IL-2 receptor subunit (IL-2Rα, IL-2Rβ, IL-2Rγ) expression on different cell populations before and after TCB2 treatment

  • Assessment of downstream signaling molecules like STAT5 phosphorylation in different cell types

What are the considerations for translating TCB2 research from mouse models to potential human applications?

Translating TCB2 research from mouse models to human applications involves several important considerations:

• Species specificity:

  • TCB2 binds specifically to human IL-2 and not mouse IL-2, unlike some other anti-hIL-2 antibodies like MAB602 that show cross-reactivity

  • This specificity needs to be considered when interpreting results from mouse models

• Humanization process:

  • The humanized TCB2 (hTCB2) has been developed with approximately 70% of the binding affinity of the murine version

  • Comparative studies show that hTCB2 maintains similar immunostimulatory and anti-tumor properties

• Dosing translation:

  • Allometric scaling principles should be applied when translating effective doses from mouse studies to potential human trials

  • Pharmacokinetic and pharmacodynamic modeling may be necessary

• Safety considerations:

  • While TCB2 preferentially expands effector over regulatory T cells, monitoring for potential autoimmune or inflammatory side effects is important

  • The combination with checkpoint inhibitors may introduce additional safety considerations

• Clinical trial design:

  • Based on preclinical data, initial human trials might focus on combination therapy with approved checkpoint inhibitors

  • Selection of cancer types should be guided by preclinical efficacy in corresponding mouse models (e.g., melanoma, colon cancer)

• Manufacturing improvements:

  • Development of a single chain complex where hIL-2 and TCB2 are connected by a linker sequence has been proposed to minimize Treg activation and simplify production

What are the technical challenges in producing consistent batches of TCB2 for research?

Producing consistent batches of TCB2 for research purposes involves addressing several technical challenges:

• Hybridoma stability:

  • Maintaining stable antibody-producing hybridoma cell lines

  • Monitoring for potential genetic drift that could affect antibody sequence or binding properties

• Expression system selection:

  • For murine TCB2, hybridoma expression systems have been used

  • For humanized TCB2, the ExpiCHO Expression System has been employed successfully

  • Different expression systems may yield antibodies with subtle differences in glycosylation patterns that could affect function

• Purification consistency:

  • Protein G resin purification with >95% purity has been used successfully

  • Consistent removal of endotoxin and other contaminants is essential, especially for in vivo applications

• Complex formation standardization:

  • The IL-2:TCB2 ratio is critical for function (typically 1:10 molecular ratio)

  • Batch-to-batch consistency in complex formation needs to be verified

• Quality control measures:

  • Functional assays such as CTLL2 cell proliferation

  • Size exclusion chromatography to confirm proper complex formation

  • Binding affinity measurement by surface plasmon resonance

  • In vivo validation of cell expansion properties in a standard mouse model

• Storage and stability:

  • While the hIL-2/TCB2 complex is stable for over a week at room temperature, long-term storage conditions and stability need to be established

  • Freeze-thaw cycles should be minimized to maintain antibody function